ANTHEM Anthem Biosciences Q4 FY26 results (Jan–Mar 2026) and concall
Anthem Biosciences reported a strong Q4 and full-year FY26 performance, driven by robust growth in its CRDMO business and significant margin expansion. The company outlined substantial capex plans for Unit 4 to double custom synthesis capacity and enhance fermentation capabilities, aiming for continued sustainable growth. Management expressed confidence in its technology-led approach, competitive positioning in peptides, and ability to maintain high profitability despite market dynamics.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 21.5%, net profit up 72.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 525 | 498 | 479 | 538 | 552 +5% | 417 −16% | 582 +22% |
| EBITDA | 201 | 167 | 198 | 195 | 226 +12% | 163 −2% | 267 +35% |
| Net profit | 170 | 128 | 123 | 148 | 198 +16% | 112 −12% | 212 +72% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
